Overview
One of the catecholamine neurotransmitters in the brain. It is derived from tyrosine and is the precursor to norepinephrine and epinephrine. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (receptors, dopamine) mediate its action.
Indication
For the correction of hemodynamic imbalances present in the shock syndrome due to myocardial infarction, trauma, endotoxic septicemia, open-heart surgery, renal failure, and chronic cardiac decompensation as in congestive failure
Associated Conditions
- Arrhythmia
- Circulatory collapse and shock
- Hypotension caused by Trauma, endotoxic septicemia, Open-heart Surgery, Renal Failure, chronic cardiac decompensation, Myocardial Infarction
- Urine flow decreased caused by Trauma, endotoxic septicemia, Open-heart Surgery, Renal Failure, chronic cardiac decompensation, Myocardial Infarction
- Decreased cardiac output caused by Trauma, endotoxic septicemia, Open-heart Surgery, Renal Failure, chronic cardiac decompensation, Myocardial Infarction
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2024/09/25 | Phase 1 | Recruiting | |||
2024/06/21 | Not Applicable | Completed | |||
2024/06/07 | Not Applicable | Recruiting | |||
2023/02/16 | Not Applicable | Recruiting | |||
2022/04/26 | N/A | Recruiting | |||
2021/02/12 | Not Applicable | UNKNOWN | Szeged University | ||
2020/09/02 | Phase 3 | Completed | |||
2020/08/25 | Phase 2 | UNKNOWN | |||
2019/09/27 | Phase 4 | Recruiting | Leiden University Medical Center | ||
2019/04/17 | N/A | Completed |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| Hospira, Inc. | 0409-5820 | INTRAVENOUS | 40 mg in 1 mL | 9/21/2023 | |
| Dr. Donna Restivo DC | 62185-0050 | ORAL | 6 [hp_X] in 1 mL | 5/23/2025 | |
| HF Acquisition Co LLC, DBA HealthFirst | 51662-1291 | INTRAVENOUS | 40 mg in 1 mL | 2/22/2024 | |
| HF Acquisition Co LLC, DBA HealthFirst | 51662-1458 | INTRAVENOUS | 1.6 mg in 1 mL | 1/27/2024 | |
| Medical Purchasing Solutions, LLC | 71872-7066 | INTRAVENOUS | 40 mg in 1 mL | 5/30/2023 | |
| Dr. Donna Restivo DC | 62185-0059 | ORAL | 8 [hp_X] in 1 mL | 5/23/2025 | |
| Henry Schein, Inc. | 0404-9981 | INTRAVENOUS | 40 mg in 1 mL | 2/17/2022 | |
| Hikma Pharmaceuticals USA Inc. | 0143-9254 | INTRAVENOUS | 40 mg in 1 mL | 5/6/2022 | |
| Baxter Healthcare Corporation | 0338-1005 | INTRAVENOUS | 80 mg in 100 mL | 7/14/2017 | |
| ProPharma Distribution | 84549-252 | INTRAVENOUS | 40 mg in 1 mL | 6/23/2025 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
Authorised | 5/27/2024 | ||
Authorised | 5/27/2024 | ||
Authorised | 5/27/2024 | ||
Authorised | 5/27/2024 | ||
Authorised | 5/27/2024 | ||
Authorised | 5/27/2024 |
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| TROPIN 200 INJECTION 200 mg/5 ml | SIN11216P | INJECTION | 200 mg/5 ml | 11/4/1999 |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| Dopamine Hydrochloride for Injection | 国药准字H20040213 | 化学药品 | 注射剂 | 8/10/2020 | |
| Dopamine Hydrochloride for Injection | 国药准字H20040214 | 化学药品 | 注射剂 | 8/10/2020 | |
| Dopamine Hydrochloride for Injection | 国药准字H20040212 | 化学药品 | 注射剂 | 8/10/2020 | |
| Dopamine Hydrochloride for Injection | 国药准字H20041357 | 化学药品 | 注射剂 | 7/3/2020 | |
| Dopamine Hydrochloride Injection | 国药准字H20253682 | 化学药品 | 注射剂 | 3/25/2025 | |
| Dopamine Hydrochloride Injection | 国药准字H20247125 | 化学药品 | 注射剂 | 6/12/2024 | |
| Dopamine Hydrochloride Injection | 国药准字H20253681 | 化学药品 | 注射剂 | 3/25/2025 | |
| Dopamine Hydrochloride Injection | 国药准字H20253216 | 化学药品 | 注射剂 | 1/14/2025 | |
| Dopamine Hydrochloride Injection | 国药准字H20233811 | 化学药品 | 注射剂 | 6/27/2023 | |
| Dopamine Hydrochloride Injection | 国药准字H20233677 | 化学药品 | 注射剂 | 6/7/2023 |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| DOPAMINE HYDROCHLORIDE S.A.L.F. CONCENTRATE FOR SOLUTION FOR INFUSION 200MG/5ML | N/A | N/A | N/A | 2/28/2025 | |
| DOPAMINE HYDROCHLORIDE CONCENTRATE FOR SOLUTION FOR INFUSION 200MG/5ML | N/A | N/A | N/A | 6/9/2025 |
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| DOPAMINE JUNO dopamine hydrochloride 200 mg/5 mL concentrated injection ampoules | 332320 | Medicine | A | 6/24/2021 | |
| DBL STERILE DOPAMINE CONCENTRATE 200mg/5mL injection ampoule | 16378 | Medicine | A | 10/8/1991 |
Help Us Improve
Your feedback helps us provide better drug information and insights.